Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA IPCA LABS ALEMBIC PHARMA/
IPCA LABS
 
P/E (TTM) x 19.5 27.4 71.4% View Chart
P/BV x 7.5 8.5 88.4% View Chart
Dividend Yield % 0.5 0.1 355.8%  

Financials

 ALEMBIC PHARMA   IPCA LABS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
IPCA LABS
Mar-19
ALEMBIC PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs6641,042 63.7%   
Low Rs412590 69.9%   
Sales per share (Unadj.) Rs208.7298.6 69.9%  
Earnings per share (Unadj.) Rs31.035.0 88.6%  
Cash flow per share (Unadj.) Rs37.149.4 75.1%  
Dividends per share (Unadj.) Rs5.503.00 183.3%  
Dividend yield (eoy) %1.00.4 278.0%  
Book value per share (Unadj.) Rs144.2247.1 58.4%  
Shares outstanding (eoy) m188.52126.35 149.2%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.62.7 94.4%   
Avg P/E ratio x17.423.3 74.5%  
P/CF ratio (eoy) x14.516.5 87.9%  
Price / Book Value ratio x3.73.3 113.0%  
Dividend payout %17.78.6 207.0%   
Avg Mkt Cap Rs m101,461103,108 98.4%   
No. of employees `000NA13.4 0.0%   
Total wages/salary Rs m7,4677,874 94.8%   
Avg. sales/employee Rs ThNM2,807.0-  
Avg. wages/employee Rs ThNM585.8-  
Avg. net profit/employee Rs ThNM329.0-  
INCOME DATA
Net Sales Rs m39,34737,732 104.3%  
Other income Rs m94577 16.3%   
Total revenues Rs m39,44138,309 103.0%   
Gross profit Rs m8,7366,901 126.6%  
Depreciation Rs m1,1521,824 63.2%   
Interest Rs m184189 97.6%   
Profit before tax Rs m7,4935,465 137.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5681,042 150.4%   
Profit after tax Rs m5,8444,422 132.1%  
Gross profit margin %22.218.3 121.4%  
Effective tax rate %20.919.1 109.7%   
Net profit margin %14.911.7 126.7%  
BALANCE SHEET DATA
Current assets Rs m19,57723,778 82.3%   
Current liabilities Rs m14,89610,975 135.7%   
Net working cap to sales %11.933.9 35.1%  
Current ratio x1.32.2 60.7%  
Inventory Days Days90104 86.5%  
Debtors Days Days4566 68.8%  
Net fixed assets Rs m27,09720,368 133.0%   
Share capital Rs m377253 149.2%   
"Free" reserves Rs m26,81130,971 86.6%   
Net worth Rs m27,18831,224 87.1%   
Long term debt Rs m4,9931,409 354.5%   
Total assets Rs m47,77845,507 105.0%  
Interest coverage x41.730.0 139.2%   
Debt to equity ratio x0.20 407.1%  
Sales to assets ratio x0.80.8 99.3%   
Return on assets %12.610.1 124.5%  
Return on equity %21.514.2 151.8%  
Return on capital %23.617.3 136.2%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m19,45317,308 112.4%   
Fx outflow Rs m6,0656,266 96.8%   
Net fx Rs m13,38811,042 121.2%   
CASH FLOW
From Operations Rs m8,1204,923 164.9%  
From Investments Rs m-7,556-1,563 483.4%  
From Financial Activity Rs m590-1,832 -32.2%  
Net Cashflow Rs m1,1531,528 75.5%  

Share Holding

Indian Promoters % 74.1 45.9 161.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 11.4 25.4%  
FIIs % 9.1 25.3 36.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 17.4 79.9%  
Shareholders   49,328 36,892 133.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SHASUN PHARMA  WYETH  TORRENT PHARMA  SUVEN LIFE SCIENCES  DR. REDDYS LAB  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 15, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - IPCA LABS COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS